Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars Payments In Medicare: CMS Signals Willingness To Change

Executive Summary

Policy of paying for all biosimilars referencing the same drug at one blended rate is under review, to the relief of product developers and other stakeholders.

Advertisement

Related Content

Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'
Medicare Coding Change For Biosimilars Could Save $65bn, Firms Say
CMS Proposal On Part D May Address Drug Costs, But Will It Target Prices?
What Renflexis Pricing Says About Medicare's Biosimilars Policy
US Biosimilars: 40% First-Cycle Approval Rate Leaves Room For Improvement
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
Doc Groups Seek To Block CMS Biosimilars Policy Via Congress
CMS Sticks With Combining Biosimilars In Single Medicare Payment Code

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel